PT Penta Valent Tbk

peve

Overview

PEVE Overview

PT Penta Valent Tbk is an Indonesia-based company that is primarily engaged in selling pharmaceutical products. The Company operates through two segments: Pharmaceutical Products and Consumer Products. Its pharmaceutical goods line offers lab reagents and medical devices. Its consumer goods line offers food, cosmetics, and toiletries. The Company serves various markets, such as government hospitals, clinics, private hospitals, pharmacies, registered drugstores, medical device stores, household stores, wholesalers, provision stores, motorcycle workshops, building material stores, and herbal stores. The Company has approximately 34 branches that are located in various cities in Indonesia.

24681012ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: PEVE

Development
Market Cap.
IDR 321.34Billion

~$20.26M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

PEVE Valuation Metrics

182

IDR

Closing Price on 2024-04-05

Price to Equity

13.17

P/E

At 13.17x P/E TTM, PEVE.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 8.9x).

Price to Book

P/B

Not available

No P/B data available for PEVE.JK.

Price to Sales

0.18

P/S

At 0.18x P/S TTM, PEVE.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Valuing PT Penta Valent Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Penta Valent Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
-0.01x
Price/Forward Earnings
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
-
PEG Ratio
-

Analyst Ratings

No analyst ratings available yet.

Last closing: IDR1822024-04-05
IDR 132.31

Slightly Lower Intrinsic Value: Analyst's intrinsic value is of PEVE is IDR132, which is 26% lower than PEVE's last closing price of IDR182 (as of 2024-04-05).

Valuation Recap of PEVE stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 13.17x is above the ID market average of 8.22x and is trading at a premium to peers in the Pharmaceuticals & Health Care Research sector (8.87x).
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.18x is below the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of PEVE's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. PEVE's P/CF ratio of -0.01x is considered healthy by analysts.●●
Max 2
Medium
Slightly Lower Intrinsic Value: Analyst's intrinsic value is of PEVE is IDR 132.31, which is 26% lower than PEVE's last closing price of IDR 182.00.
Max 3

Peers

PEVE Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
KAEFKimia Farma Tbk.5.04T8.99T 10.19T -0.17T -30.26
Competitiveness Recap of PEVE stock
WeightNotesScore
High
At a market cap of IDR 321.34 billion, PEVE.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of 13.17, PEVE.JK ranks 8 out of 10 companies in the Healthcare sector for P/E value. The average PE is -18.74 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of 13.17, PEVE.JK is trading at a higher PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 8.87). false
Max 2
Medium
At a revenue of IDR 1.80 trillion, PEVE.JK ranks 9 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of IDR 0.02 trillion, PEVE.JK ranks 9 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of PEVE

Growth Forecasts

No data available

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are shrinking at a projected rate of -1.18% against the IDX average of +12.0%.

Pharmaceuticals & Health Care Research sector overview
No data is available for PEVE at the moment.
Future growth prospect of PEVE
WeightNotesScore
High
PEVE's projected growth rate of -1.18% is below the ID market average of 11.98%.●●●
Max 3
High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 11.14% in 2024. This number is higher than the previous year 2023's growth rate of 2.48%. This bodes well for PEVE's revenue growth prospects in the next 2 years. ●●
Max 3
Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 2.56% in 2024. This number is higher than the previous year 2023's EPS growth of -8.71%. false
Max 3
Medium
PEVE and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for PEVE's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

Sukismo15.2 years
Franxiscus Afat Adinata Nursalim
Director
Melisa Patricia
Director
NamePositionShares%
Franxiscus Afat Adinata NursalimDirector38,850,0002.2
Expressed in millions IDR, unless otherwise stated

Ownership

PEVE Ownership

Others
12.87%
Insiders
87.13%
Institutions
0%
NameNumber of SharesOwnership (%)Value
Pt Tancorp Mega Buana988,750,00056179.95B
Public (Scripless)314,275,00017.857.20B
Pt Maramakmur Selaras216,112,50012.2439.33B
Pt Multi Pidotama Mandiri207,637,50011.7637.79B
Franxiscus Afat Adinata Nursalim38,850,0002.27.07B
No data is available for PEVE at the moment.